Yeah, I’m honestly not sure why I try and post t
Post# of 110
I’m in the camp though that thinks this probably doesn’t get through the phase 2 trials without a BO. I’m not sure big pharma wants the share price creeping up before they offer something. I am curious your thoughts about what happens to the other solid tumor targets? Breast, ovarian adjunct therapy would be an incredible advancement. If this is sold, I would hope the valuation includes the eventual impact on all these various cell lines